Rate My Professor Lisa Lincz

Lincz's academic interests and research specializations lie primarily in haematology, with fields of research allocated as haematology (50%), cancer cell biology (25%), and haematological tumours (25%). Key expertise encompasses investigating circulating microparticles and extracellular vesicles, genetic susceptibility to disease and treatment toxicity, mechanisms of snakebite coagulopathy, novel targets on leukaemia cell surfaces, and epigenetics of atherothrombotic disease. She has contributed to 119 publications garnering over 3,461 citations, including prominent recent papers: "Modeling the Bone Marrow Microenvironment to Better Understand the Pathogenesis, Progression, and Treatment of Hematological Cancers" (Cancers, 2025), "Combination therapy in cancer: The potential of tetrandrine as a polytherapy for acute myeloid leukemia" (Biochimica et Biophysica Acta Reviews on Cancer, 2025), "High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia" (Cancers, 2024), "Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia" (International Journal of Molecular Sciences, 2023), and "A comparative evaluation of three consecutive artificial intelligence algorithms released by Techcyte for identification of blasts and white blood cells in abnormal peripheral blood films" (International Journal of Laboratory Hematology, 2024). Lincz has secured competitive grants from institutions like Hunter Medical Research Institute and NHMRC, including a $1,108,000 NHMRC project on stroke genetics (2009) and equipment grants exceeding $140,000. Early accolades include the Newcastle and Hunter Junior Chamber Special Commendation Prize ($1,500, 2000) and PULSE Education Prize ($3,000, 2003). Her contributions advance biomarker identification, drug targeting in haematological cancers, and diagnostic innovations like AI in blood film analysis.